Aragen Bioscience Expands RapTr Cell Line Development Services
March 19, 2018
San Francisco, CA — March 19, 2018 — Aragen Bioscience, Inc, a leading pre-clinical CRO specializing in monoclonal antibody and other large-molecule product development, announced today that their RapTr™ Cell Line Development Services have been expanded to include CHO-GS cell lines. The company is introducing their new services at the Bioprocess International West Conference in San Francisco this week.
RapTr™ services combine proven host cell lines and vector combinations with an innovative clone selection process. This results in a highly flexible and customizable platform that rapidly delivers high titers, allowing researchers to characterize and evaluate product quality at all stages of development — from early-stage discovery to manufacturing. Both RapTr cell lines are regulatory-friendly and royalty-free.
“We’re excited to broaden our RapTr™ services to include the CHO-GS cell line. This expansion will give our clients much more flexibility with development decisions”, said Virginie Menard Rose, Ph.D., Director of Cell Line Development and Upstream Process Development. “Our royalty-free, fee-for-service approach also eliminates the requirement for negotiating a third-party cell licensing agreement.
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of In Vitro and In Vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products.